Refine Results
Sort By
From
To
Page 1
Page 1
Biomarkers for alzheimer’s disease drug development
Aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Alzheimers disease : Cellular and molecular aspects of Amyloid beta
This book contains a survey of present-day research into the biomedical fundamentals of Alzheimer’s disease (AD). It contains 20 chapters dealing with widely ranging topics, all of which have a bearing upon the understanding and treatment of AD. Starting with a broad survey of the contribution that the various microscopical techniques (light microscopy, electron microscopy, atomic force microscopy)
Abeta Peptide and Alzheimers Disease : Celebrating a Century of Research
Abeta Peptide and Alzheimer’s Disease summarizes current knowledge of beta-amyloid peptide (Aß) and its role as the major culprit in Alzheimer’s Disease (AD), shown by recent advances in genetics and brain biochemistry.the book covers fundamental biochemical studies on the Aß peptide, the genetic impact on Aß expression and processing, and various AD therapeutic strategies that target Aß. Although specifically focusing on Aß and AD, there is also some discussion on the similarity and differences of this peptide and AD with other amyloidogenic diseases.
Alzheimers Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that robs the minds of our elderly population. Approximately one in every eight adults over the age of 65 and nearly half of those over 85 are afflicted with this disease. The aging population in developed societies will impose an ever increasing socioeconomic threat in the future. Current medicines for AD patients are mainly symptomatic treatments and a huge unmet medical need exists to slow the progression of this disease. A great deal of research has been dedicated to understanding the pathogenesis of AD from which comes many ideas for intervening with its progression. Some of these ideas have been fast-tracked to clinical trials due to the availability of medicines with proven clinical efficacies for other diseases (e.g. atorvastatin, simvastatin, rosiglitazone and clioquinol) while others represent novel chemical entities (e.g. glycogen synthase kinase-3 inhibitors).
